Compare Stocks: AMRN and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.03	$12.96 ▼ $20.90	$287.91M	0.76	80,412 shs	50,664 shs
UTHR United Therapeutics	$494.63 -0.5%	$515.48	$408.75 ▼ $609.35	$21.22B	0.56	613,512 shs	1.48 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-1.23%	-3.06%	-14.97%	-6.64%
UTHR United Therapeutics	0.00%	-0.50%	-5.06%	-7.82%	+22.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.03	$12.96 ▼ $20.90	$287.91M	0.76	80,412 shs	50,664 shs
UTHR United Therapeutics	$494.63 -0.5%	$515.48	$408.75 ▼ $609.35	$21.22B	0.56	613,512 shs	1.48 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-1.23%	-3.06%	-14.97%	-6.64%
UTHR United Therapeutics	0.00%	-0.50%	-5.06%	-7.82%	+22.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.33	Sell	$13.00	-4.62% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	30.60% Upside

Current Analyst Ratings Breakdown

Latest AMRN and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/6/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$515.00
8/6/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$704.00 ➝ $677.00
7/31/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/23/2026	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$685.00 ➝ $687.00
7/17/2026	AMRN Amarin	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$620.00 ➝ $613.00
7/7/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$701.00 ➝ $704.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$213.65M	1.35	$0.36 per share	37.76	$22.07 per share	0.62
UTHR United Therapeutics	$3.15B	6.73	$33.00 per share	14.99	$164.81 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.70	16.68	2.48	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest AMRN and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.67	2.67
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	4.21%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

AMRN and UTHR Headlines

Recent News About These Companies

United Therapeutics Insider Sold Shares Worth $4,712,580, According to a Recent SEC Filing

September 19 at 9:41 AM | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,129,582.00 in Stock

September 19 at 6:37 AM | insidertrades.com

179,235 Shares in United Therapeutics Corporation $UTHR Bought by Bank of America Corp DE

September 19 at 3:22 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

September 18 at 5:07 PM | marketbeat.com

Biotech Options Buzz: UTHR, NMRA, EWTX

September 18 at 11:46 AM | schaeffersresearch.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,763,205.00 in Stock

September 18 at 6:37 AM | insidertrades.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock

September 18 at 4:22 AM | americanbankingnews.com

Corient Private Wealth LP Reduces Stake in United Therapeutics Corporation $UTHR

September 18 at 3:20 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,763,205.00 in Stock

September 17 at 5:07 PM | marketbeat.com

Ameritas Advisory Services LLC Sells 5,124 Shares of United Therapeutics Corporation $UTHR

September 17 at 3:11 AM | marketbeat.com

United Therapeutics Insider Sold Shares Worth $4,789,152, According to a Recent SEC Filing

September 16, 2026 | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by Analysts

September 16, 2026 | americanbankingnews.com

United Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 16, 2026 | marketbeat.com

Nilda Mesa Sells 228 Shares of United Therapeutics (NASDAQ:UTHR) Stock

September 15, 2026 | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Purchases New Stake in United Therapeutics Corporation $UTHR

September 15, 2026 | marketbeat.com

United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

WINTON GROUP Ltd Trims Holdings in United Therapeutics Corporation $UTHR

September 14, 2026 | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,772,325.00 in Stock

September 14, 2026 | americanbankingnews.com

National Pension Service Sells 2,208 Shares of United Therapeutics Corporation $UTHR

September 13, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN and UTHR Company Descriptions

Amarin NASDAQ:AMRN

$13.63 -0.24 (-1.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.63 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

United Therapeutics NASDAQ:UTHR

$494.63 -2.64 (-0.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$494.73 +0.10 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN and UTHR Company Descriptions

Amarin NASDAQ:AMRN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN and UTHR Company Descriptions

Amarin NASDAQ:AMRN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools